



Corporate Press Release

3 December 2010

New Structure for Norgine Development Anticipates Future Requirements

Norgine today announces a new structure for its Development Department.

Norgine has decided to form three Therapy Area Development Teams each led by a Therapy Area Director with strong drug development experience. These teams consist of cross functional expertise in clinical development, regulatory development and project management to lead Norgine's R&D pipeline activities. The Therapy Area Directors will be leading the projects within their teams and will have responsibility for the line management of their cross functional staff and for establishing close alignment of any other resources required to successfully deliver their projects.

In addition Norgine has merged the leadership of the Medical and Regulatory teams with responsibility for currently marketed products and who will have input into late phase development pipeline projects. The country teams will now have a single line management function who will be able to ensure alignment of Development's country based staff to ensure resources are most effectively utilized.

The above changes have also allowed a refocusing of preclinical activities and creation of a new Preclinical Development team who will have responsibility for leading Norgine's ambition to increasingly be able to deliver our own innovative projects from new collaborative discovery partnerships to take these into full development for our own commercialisation and regional outlicensing.

Stuart Dollow, Chief Development Officer for Norgine said, 'These changes reflect the changes in Norgine's capabilities and requirements for future success. Formation of a dedicated Preclinical Development team will give us greater independence in years to come by having greater control of our own assets that we can more effectively deliver through the new Therapy Area Teams. Transforming our Development capabilities will enable us to continue to grow in a new way in the future as our existing portfolio matures.'

'The creation of Medical and Regulatory Affairs also provides us with an effective structure to successfully understand and address market requirements in our development plans to ensure we fulfill patient needs as

well as those of the payers who are playing an increasing gatekeeping role. This team will also be a strong group of experts to provide input to successful commercial activities. This new structure reflects Norgine's ambition for further growth in existing and new products.'

ENDS

About Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2009, Norgine's net product sales were €253 million, the 23rd year of double-digit growth at constant exchange rates. The company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and supportive care. The company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, XIFAXAN[®] for the treatment of travellers diarrhoea and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France. www.norgine.com

Norgine Contact

Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com